1 min read.Updated: 22 Jun 2022, 02:00 PM ISTLivemint
The pharma stock is down 13% in 2022 (YTD) so far
Listen to this article
During its investor day, Dr Reddy's re-iterated its 25%/25% EBITDA/ROCE targets & elaborated on the levers that will help achieve these. Dr Reddy's aims for sustainable double-digit top-line growth, & plans to expand existing business and seek new opportunities such as Biologics CDMO & CGT, highlighted Jefferies in a note.